** Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 2% to $62.70
** Co says the U.S. FDA has given expanded approval for Iluvien to treat chronic, non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)
** NIU-PS is characterized by inflammation of the retina or optic nerve of the eye
** Iluvien is already approved by the FDA to treat another eye condition called diabetic macular edema $(DME.AU)$
** Co plans to market Iluvien under the combined label in the U.S. later this year
** Up to last close, ANIP has fallen 7.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。